尿DKK3:慢性肾脏病进展与死亡的新生物标志物
该研究前瞻性纳入两个独立队列共351例2-3期CKD患者,评估尿DKK3与CKD进展的关系。中位随访36个月,复合终点为血肌酐翻倍、终末期肾病或死亡。结果显示基线尿DKK3最高组是肾脏进展的独立危险因素,且不受CKD病因影响。
要点
- 尿DKK3高水平是CKD进展的独立预测因子
- 尿DKK3预测价值不受CKD病因影响
- 尿DKK3可能用于优化CKD分期和监测治疗反应
核心结论
- 尿DKK3可识别CKD进展高风险患者,与肾脏损伤病因无关。
- 尿DKK3可能作为肾脏疾病进展的有用生物标志物,帮助临床优化分期和监测治疗反应。
研究设计与样本
- 前瞻性研究两个独立队列,共351例2期和3期CKD患者。
- Progreser队列为不同病因的CKD患者,Pronedi队列为101例明显糖尿病肾病患者的队列。
- 中位随访时间分别为36个月(IQR 30-39)和36个月(IQR 16-48)。
- 复合主要终点为血清肌酐升高50%、终末期肾病或死亡。
主要发现
- 基线尿DKK3在Progreser队列中位数为2200 pg/mg(IQR 671-7617),在Pronedi队列中为3042 pg/mg(IQR 661-9747)。
- 两个队列间及不同CKD病因间尿DKK3比值无统计学显著差异。
- 达到主要终点患者的基线尿DKK3显著更高。
- Cox比例风险模型中,最高水平尿DKK3是Progreser队列肾脏进展的独立因素(HR 1.91,95%CI 1.04-3.52),也是Pronedi队列的独立因素(HR 3.03,95%CI 1.03-8.92)。
- 尿DKK3在随后数月逐渐升高,尤其在蛋白尿较高的患者中。
临床怎么用
- 临床可考虑检测尿DKK3以识别CKD进展高风险患者,辅助风险分层。
- 尿DKK3水平不受CKD病因影响,可能广泛适用于不同病因的CKD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney fibrosis has been reported to be a prognostic factor in chronic kidney disease (CKD) progression. Previous studies have shown that the assessment of urinary Dickkopf-3 (uDKK3), a stress-induced tubular epithelial-derived profibrotic glycoprotein, might be a potential tubulointerstitial fibrosis biomarker and might identify patients at short-term risk of glomerular filtration rate loss. We aim to evaluate uDKK3 as a potential biomarker for progression of CKD in a cohort with various aetiologies of CKD and subsequently in an overt diabetic nephropathy cohort. METHODS: We prospectively studied two independent cohorts comprising a total of 351 patients with Stages 2 and 3 CKD. Combined primary outcome consisted of a 50% increase in serum creatinine, end-stage kidney disease or death. The Progreser cohort included patients with heterogeneous aetiologies and the Pronedi cohort (101 patients) with overt diabetic nephropathy. The median follow-up time was 36 months [interquartile range (IQR) 30-39] and 36 (16-48), respectively. RESULTS: At baseline, median uDKK3 was 2200 pg/mg (IQR 671-7617) in the Progreser cohort and 3042 pg/mg (IQR 661-9747) in the Pronedi cohort. There were no statistically significant differences in the uDKK3 ratio between both cohorts nor between CKD aetiologies. Baseline uDKK3 was significantly higher in patients who reached the primary outcome. In the Cox proportional hazards model, the highest levels of uDKK3 were found to be an independent factor for renal progression in the Progreser cohort {hazard ratio [HR] 1.91 [95% confidence interval (CI) 1.04-3.52]} and in the Pronedi cohort [HR 3.03 (95% CI 1.03-8.92)]. uDKK3 gradually increased in the following months, especially in patients with higher proteinuria. Treatment with renin-angiotensin-aldosterone system blockers did not modify uDKK3 after 4 or 12 months of treatment. CONCLUSIONS: uDKK3 identifies patients at high risk of CKD progression regardless of the cause of kidney injury. uDKK3 might serve as a useful biomarker for kidney disease progression and therefore could be used by clinicians to optimize staging for renal progression and monitor the response to potential treatments.
引用
- Sánchez-Álamo B, García-Iñigo FJ, Shabaka A, et al. Urinary Dickkopf-3: a new biomarker for CKD progression and mortality. Nephrol Dial Transplant. 2021. PMID: 34145894. doi:10.1093/ndt/gfab198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。